___

• 1. Dyken PR. Neuroprogressive disease of postinfectious origin: a review of a resurging subacute sclerosing panencephalitis (SSPE). MRDD Research Reviews 2001; 7: 217-25. 2. Garg RK. Subacute sclerosing panencephalitis. Postgrad Med J 2002; 78; 63-70. 3. Greenfield JG. Encephalitis and encephalomyelitis in England and Wales during last decade. Brain 1950; 73: 141-66. 4. Dawson JR. Cellular inclusions in cerebral lesions of epidemic encephalitis. Am J Pathol 1933; 9: 7-15. 5. Park SY, Kohl S. Subacute Sclerosing Panencephalitis in an Identical Twin. Pediatrics 1999; 104: 1390-4. 6. Connolly JH, Allen IV, Hurwitz IJ, et al. Measles virus antibody and antigen in subacute sclerosing panencephalitis. Lancet 1967; 1: 542-4. 7. Onal AE, Gürses C, Direskeneli GS, et al. Subacute sclerosing panencephalitis surveillance study in Istanbul. Brain Dev 2006; 28: 183-9. 8. Halsey NA, Modlin JF, Jabbour JT, et al. Risk factors in subacute sclerosing panencephalitis: a case-control study. Am J Epidemiol 1980; 111: 415-24. 9. Anlar B, Köse G, Gürer Y, et al. Changing epidemiological features of subacute sclerosing panencephalitis. Infection 2001; 29: 192-5. 10. Rota PA, Bellini WJ. Update on the global distribution of genotypes of wild type measles viruses. JID 2003:187 (Suppl 1). 11. Rima BK, Duprex WP. Morbilliviruses and human disease. J Pathol 2006; 208: 199-214. 12. Schneider-Schaulies S, ter Meulen V. Pathogenic aspects of measles virus infections. Arch Virol Suppl 1999; 15: 139-58. 13. Norrby E, Kristensson K. Measles virus in the brain. Brain Res Bull 1997; 44: 213-20. 14. Rima BK, Duprex WP. Molecular mechanisms of measles virus persistence. Virus Research 2005; 111: 132-47. 15. Bellini WJ, Rota JS, Lowe LE, et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles Immunization than was previously recognized. J infect Dis 2005; 192: 1686-93. 16. Miki K, Komase K, Mgone CS, et al. Molecular analysis of measles virus genome derived from SSPE and acute measles patients in Papua New Guinea. J Med Virol 2002; 68:105-12. 17. Cosby SL, Duprex WP, Hamill LA, et al. Approaches in the understanding of morbillivirus neurovirulence. J Neurovirol 2002; 8 Suppl 2: 85-90. 18. Schneider-Schaulies J, Meulen V, Schneider-Schaulies S. Measles infection of the central nervous system. J Neurovirol 2003; 9: 247-52. 19. McQuaid S, Cosby SL. An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis. Lab Invest 2002; 82: 403-9. 20. Schneider-Schaulies J, ter Meulen V, Schneider-Schaulies S. Measles virus interactions with cellular receptors: consequences for viral pathogenesis. J Neurovirol 2001; 7: 39. 21. Nester MJ. Use of a brief assessment examination in a study of subacute sclerosing panencephalitis. J Child Neurol 1996; 11: 173-80. 22. Anlar B, Guven A, Kose G, et al. Lymphocyte subsets, TNF alpha and interleukin-4 levels in treated and untreated subacute sclerosing panencephalitis patients. J Neuroimmunol 2005; 163: 195-8. 23. Aysun S, Sanal O, Renda Y, et al. Cell mediated immunity in patients with subacute sclerosing panencephalitis. Brain Dev 1984; 6: 391-6. 24. Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J Infect Dis 1993;168: 275-81. 25. Yentür SP, Gürses C, Demirbilek V. Alterations in cell-mediated immune response in subacute sclerosing panencephalitis. J Neuroimmunol 2005;170: 179-85. 26. Karp CL, Wysocka M, Wahl LM, et al. Mechanisms of suppression of cell-mediated immunity by measles virus. Science 1996; 273: 228- 31. 27. Saruhan-Direskeneli G, Gürses C, Demirbilek V, et al. Elevated interleukin-12 and CXCL10 in subacute sclerosing panencephalitis. Cytokine 2005; 32: 104-10. 28. Haspolat S, Anlar B, Kose G, Coskun M, Yegin O. Interleukin-1beta, interleukin-1 receptor antagonist levels in patients with subacute sclerosing panencephalitis and the effects of different treatment protocols. J Child Neurol 2001; 16: 417-20. 29. Gilden DH, Devlin ME, Burgoon MP, Owens GP. The search for virus in multiple sclerosis brain. Mult Scler 1996; 2: 179-83. 30. Burgoon MP, Keays KM, Owens GP, et al. Laser-capture microdissection of plasma cells from subacute sclerosing panencephalitis brain reveals intrathecal disease-relevant antibodies. Proc Natl Acad Sci U S A 2005; 102: 7245-50. 31. Anlar B, Pinar A, Yasar Anlar F, et al. Viral studies in the cerebrospinal fluid in subacute sclerosing panencephalitis. J Infect 2002; 44: 176-80. 32. Tasdemir N, Ece A, Tekes S, et al. Angiotensin-converting enzyme and angiotensin II type 1 receptor gene polymorphisms in children with subacute sclerosing panencephalitis. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 445-8. 33. Gungor S, Olmez A, Pinar Arikan Firat, Haliloğlu G, Anlar B. Serum retinol and beta-carotene levels in subacute sclerosing panencephalitis. J Child Neurol 2007; 22: 341-3. 34. Jabbour JT, Garcia JH, Lemmi H, et al. Subacute sclerosing panencephalitis. A multidisciplinary study of eight cases. JAMA 1969; 207: 2248-54. 35. Campbell C, Levin S, Humphreys P, et al. Subacute sclerosing panencephalitis: results of the Canadian paediatric surveillance program and review of the literature. BMC Pediatrics 2005; 15: 5-47. 36. Dyken P, Dotson P, Maertens P. The neurological disability index (NDI) in subacute sclerosing panencephalitis (SSPE). In: Bergamini F, Defanti CA, Ferrante P (eds). Subacute Sclerosing Panencephalis: a reappraisal. Bergamo: Elsevier Science Publishers B.V. (Biomedical Division), 1986: 109-17. 37. Pampiglione G, Harden A. Neurophysiological aspects of SSPE. In: Program of the Second International Symposium on Subacute Sclerosing Panencephalitis. Bergamo, Elsevier Press, 1985: 33. 38. Anlar B, Yalaz K, Ustacelebi S. Symptoms and clinical signs, laboratory data in 80 cases of subacute sclerosing panencephalitis. Rev Neurol 1988; 144: 829-32. 39. Salehi H, Wolf S, McGoldrick P, Moshé S. Subacute sclerosing panencephalitis with atypical features. Pediatr Neurol 2005; 33: 280-2. 40. Demirbilek V, Benbir G, Cokar O, et al. Tonic seizures in subacute sclerosing panencephalitis: a video-illustration of two cases. Epileptic Disord 2005; 7: 221-5. 41. Kubota T, Okumura A, Takenaka J, et al. A case of subacute sclerosing panencephalitis preceded by epileptic seizures: evolutional EEG changes. Brain Dev 2003; 25: 279-82. 42. Aydin OF, Karakurt C, Senocak F, et al. Heart rate variability and autonomic dysfunction in SSPE. Pediatr Neurol 2005; 32: 184-9. 43. Chung BH, Ip PP, Wong VC, et al. Acute fulminant subacute sclerosing panencephalitis with absent measles and PCR studies in cerebrospinal fluid. Pediatr Neurol 2004; 31: 222-4. 44. Simsek E, Ozturk A, Yavuz C, Kocabay K. Subacute sclerosing panencephalitis (SSPE) associated with congenital measles infection. Turk J Pediatr 2005; 47: 58-62. 45. Tan H, Orhan A, Buyukavci M, Kocer I. Pseudotumor cerebri secondary to subacute sclerosing panencephalitis. J Child Neurol 2004; 19: 627-9. 46. Honarmand S, Glaser CA, Chow E, et al. Subacute sclerosing panencephalitis in the differential diagnosis of encephalitis. Neurology 2004; 63: 1489-93. 47. Serdaroglu A, Gucuyener K, Dursun I, et al. Macular retinitis as a first sign of subacute sclerosing panencephalitis: the importance of early diagnosis. Ocul Immunol Inflamm 2005; 13: 405-10. 48. Aydin OF, Orer H, Gurer YK. Subacute sclerosing panencephalitis: a cause of acute vision loss. Pediatr Neurol 2004; 31: 214-7. 49. Dyken PR. Subacute sclerosing panencephalitis. Neurol Clin 1985; 3: 179-95. 50. Ekmekci O, Karasoy H, Gokcay A, Ulku A. Atypical EEG findings in subacute sclerosing panencephalitis. Clin Neurophysiol 2005; 116: 1762-7. 51. Anlar B, Saatci I, Kose G, Yalaz K. MRI findings in subacute sclerosing panencephalitis. Neurology 1996;47:1278-83. 52. Anlar B, Soylemezoglu F, Aysun S, et al. Tissue inflammatory response in subacute sclerosing panencephalitis (SSPE). J Child Neurol 2001; 16: 895-900. 53. Ozturk A, Gurses C, Baykan B, et al. Subacute sclerosing panencephalitis: clinical and magnetic resonance imaging evaluation of 36 patients. J Child Neurol 2002; 17: 25-9. 54. Aydin K, Tatli B, Ozkan M, et al. Quantification of neurometabolites in subacute sclerosing panencephalitis by 1H-MRS. Neurology 2006; 67: 911-3. 55. Tha KK, Terae S, Kudo K, et al. Early detection of subacute sclerosing panencephalitis by high b-value diffusion-weighted imaging: a case report. J Comput Assist Tomogr 2006; 30: 126-30. 56. Trivedi R, Gupta RK, Agarawal A, et al. Assessment of white matter damage in subacute sclerosing panencephalitis using quantitative diffusion tensor MR imaging. AJNR Am J Neuroradiol 2006; 27: 1712-6. 57. Dyken PR, Swift A, DuRant RH. Long-term follow-up of patients with subacute sclerosing panencephalitis treated with inosiplex. Ann Neurol 1982;11:359-64. 58. Maimone D, Grimaldi LM, Incorpora G, et al. Intrathecal interferon in subacute sclerosing panencephalitis. Acta Neurol Scand 1988; 78: 161-6. 59. Gascon GG. International Consortium on Subacute Sclerosing Panencephalitis. Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): international multicenter study. J Child Neurol 2003; 18: 819-27. 60. Gascon G, Yamani S, Crowell J, et al. Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis. Brain Dev 1993; 15: 346-55. 61. Anlar B, Aydin OF, Guven A, et al. Retrospective evaluation of interferon-beta treatment in subacute sclerosing panencephalitis. Clin Ther 2004; 26: 1890-4. 62. Güngör S, Anlar B, Turan N, et al. Antibodies to borna disease virus in subacute sclerosing panencephalitis. Ped Infect Dis J 2005; 24: 833-4. 63. Del Toro-Riera M, Macaya-Ruiz A, Raspall-Chaure M, et al. Subacute sclerosing panencephalitis: combined treatment with interferon alpha and intraventricular ribavirin. Rev Neurol 2006; 42: 277-81. 64. Hosoya M, Shigeta S, Mori S, et al. High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2001; 45: 943-55. 65. Anlar B, Gucuyener K, Imir T, et al. Cimetidine as an immunomodulator in subacute sclerosing panencephalitis: a double blind, placebo-controlled study. Pediatr Infect Dis J 1993; 12: 578-81. 66. Gurer YK, Kukner S, Sarica B. Intravenous gamma-globulin treatment in a patient with subacute sclerosing panencephalitis. Pediatr Neurol 1996; 14: 72-4. 67. Al Rajeh S. Response to cytotoxic therapy in a female patient from Saudi Arabia. Published in correspondence section in the Lancet in 1994. 68. Nakayama T, Fujino M, Yoshida N. Molecular epidemiology of measles virus in Japan. Ped Int 2004; 46: 214-23. 69. Campbell H, Andrews N, Brown KE, Miller E. Review of the effect of measles vaccination on the epidemiology of SSPE. Int J Epidemiol 2007; 36: 1334-48. 70. Oldstone MB, Dales S, Tishon A, et al. A role for dual viral hits in causation of subacute sclerosing panencephalitis. J Exp Med 2005; 202: 1185-90. 71. Otaki M, Sada K, Kadoya H, et al. Inhibition of measles virus and subacute sclerosing panencephalitis virus by RNA interference. Antiviral Research 2006; 70: 105-11.